Immunovia Full Year Report 2020 News provided by Share this article LUND, Sweden, Feb. 17, 2021 /PRNewswire/ -- Immunovia has today published its Full Year Report for January - December 2020. It is available on Immunovia's website. "Immunovia is approaching commercial breakthrough: A sales start is planned for the first quarter of 2021. We look forward to helping patients through early detection of pancreatic cancer. All Immunovia employees are incredibly proud of the progress we have made in 2020, especially with regard to the October 2020 milestone when we were able to document 94 percent accuracy for IMMray™ PanCan-d, the company's first blood test for the diagnosis of pancreatic cancer in the early stages of the disease when it is still possible to conduct surgery. The result opens the way for significantly improved care and survival of patients suffering from this deadly disease.